{"id":"diacetylmorphine-liquid-oral","safety":{"commonSideEffects":[{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Dependence"}]},"_chembl":{"chemblId":"CHEMBL2106627","moleculeType":"Small molecule","molecularWeight":"405.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Diacetylmorphine is a semi-synthetic opioid derived from morphine. It crosses the blood-brain barrier more readily than morphine due to its lipophilicity, and is rapidly deacetylated to morphine and 6-monoacetylmorphine in the body. It acts as an agonist at opioid receptors, particularly mu receptors, producing potent analgesic and psychoactive effects. In the context of this Phase 3 trial at UBC, it is being investigated as a pharmaceutical-grade oral formulation for opioid use disorder or chronic pain management in a controlled medical setting.","oneSentence":"Diacetylmorphine (heroin) is an opioid agonist that binds to mu, delta, and kappa opioid receptors in the central nervous system to produce analgesia, euphoria, and sedation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:21.288Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder (maintenance therapy)"},{"name":"Chronic pain in opioid-tolerant patients"}]},"trialDetails":[{"nctId":"NCT01447212","phase":"PHASE3","title":"Study to Assess Longer-term Opioid Medication Effectiveness (SALOME)","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-12","conditions":"Opioid Dependence, Heroin Dependence","enrollment":202}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Diacetylmorphine, liquid oral","genericName":"Diacetylmorphine, liquid oral","companyName":"University of British Columbia","companyId":"university-of-british-columbia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Diacetylmorphine (heroin) is an opioid agonist that binds to mu, delta, and kappa opioid receptors in the central nervous system to produce analgesia, euphoria, and sedation. Used for Opioid use disorder (maintenance therapy), Chronic pain in opioid-tolerant patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}